M&A slows to a trickle in 2017, but Big Pharma could be on deck for mega deals
Free-flowing cash for startups, sky-high valuations, and uncertainty about tax reform led to unexpected stagnation in M&A this year. But big deals could be on the horizon as large pharmaceutical companies get squeezed to deliver top line growth.
After a lackluster 2016 (thanks to uncertainty in an election year), many experts in the industry predicted — with President Trump firmly seated in the White House — that we would see an uptick in mergers and acquisitions in 2017. They were wrong. Besides Gilead’s nearly $12 billion move on Kite, 2017 was rather quiet on the M&A front, according to a new report by EvaluatePharma’s EP Vantage.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.